Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
After the KFDA (Korea Food and Drug Administration) approval of a new drug, an annual report
of the drug's safety and efficacy data must be reported to the Health Authority in 6 years.
In this Observational study, we will investigate the basic demographic, medical history,
concomitant drug use, as well as dosing information of multiple myeloma patients using
bortezomib (Velcade).